| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14779072.2.5.661 |
| P698 | PubMed publication ID | 15350168 |
| P2093 | author name string | Erika J Martin | |
| Marcus E Carr | |||
| P2860 | cites work | Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque | Q24339425 |
| The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor | Q27732597 | ||
| A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S | Q28262397 | ||
| Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells | Q28646327 | ||
| Ongoing NovoSeven trials | Q33344984 | ||
| Clinical use of recombinant FVIIa (rFVIIa). | Q33584641 | ||
| The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor | Q33901363 | ||
| Inhibitor antibodies to factor VIII and factor IX: management | Q33987098 | ||
| Pharmacokinetics of recombinant activated factor VII (rFVIIa). | Q34090271 | ||
| The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. | Q34090287 | ||
| Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis | Q34090313 | ||
| Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine | Q34172504 | ||
| AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER. | Q34257237 | ||
| WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. | Q34257361 | ||
| Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development | Q34362575 | ||
| Off-label use of recombinant factor VIIa in patients following bone marrow transplantation | Q34380751 | ||
| Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa | Q34529736 | ||
| Haematological care of the Jehovah's Witness patient | Q34929104 | ||
| NovoSeven: mode of action and use in acquired haemophilia | Q34982411 | ||
| Update on Novo Nordisk's clinical trial programme on NovoSeven® | Q35563637 | ||
| Monitoring coagulation and the clinical effects of recombinant factor VIIa | Q35661480 | ||
| Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors | Q35771690 | ||
| Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII | Q37042626 | ||
| Application of a zeolite hemostatic agent achieves 100% survival in a lethal model of complex groin injury in Swine | Q39379993 | ||
| Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. | Q41657021 | ||
| Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency | Q41713849 | ||
| Autoactivation of human recombinant coagulation factor VII. | Q42193518 | ||
| Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa | Q43646153 | ||
| Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. | Q44213377 | ||
| Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate | Q44234275 | ||
| Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers | Q44761447 | ||
| A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group | Q45856561 | ||
| Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. | Q45871242 | ||
| Pharmacokinetics and pharmacodynamics of recombinant factor VIIa | Q45871531 | ||
| Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency | Q45885141 | ||
| Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). | Q53386785 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 661-674 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Expert Review of Cardiovascular Therapy | Q15733727 |
| P1476 | title | Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential | |
| P478 | volume | 2 |
| Q36349585 | Management of bleeding emergencies: when to use recombinant activated factor VII. |
| Q36284640 | Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma |
| Q35544621 | Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding |
| Q38388574 | Use of Activated Factor VII in Patients with Diffuse Alveolar Hemorrhage: A 10 Years Institutional Experience |
Search more.